US-based therapeutic products developer Tris Pharma has acquired Pfizer’s wholly-owned subsidiary NextWave Pharmaceuticals, for an undisclosed amount.

The deal expands Tris Pharma’s portfolio focused on the treatment of attention deficit hyperactivity disorder (ADHD) by adding two therapies created by NextWave, Quillivant XR and QuilliChew ER.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Quillivant XR is an oral liquid methylphenidate, while QuilliChew ER is a methylphenidate chewable tablet. Both are extended-release formulations and central nervous system (CNS) stimulants indicated for ADHD.

Tris Pharma co-developed these ADHD treatments with NextWave using its LiquiXR platform. Tris continued to manufacture the products even after Pfizer acquired NextWave in 2012.

The company’s president and CEO Ketan Mehta said: “As co-developer of Quillivant XR and QuilliChew ER, we are excited to bring commercialisation of these products in house and expand our ADHD portfolio.

“As co-developer of Quillivant XR and QuilliChew ER, we are excited to bring commercialisation of these products in house.”

“To further support our newest acquisition, Tris is expanding our commercial footprint and building a world class medical affairs group.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Tris’ portfolio for ADHD comprises a liquid amphetamine called DYANAVEL XR. The product was launched in 2016 for the treatment of the disorder in children aged six years and above.

Tris Pharma chief medical officer Barry Herman said: “Our newest acquisition brings us one step closer to realising our corporate mission, to develop and expand offerings to meet unmet needs for all patients.

“With three treatment options for patients with ADHD, Tris now offers a broad, established product portfolio with both stimulant classes in the ADHD space.”

In addition to DYANAVEL XR, the company provides a variety of generics such as Dexmethylphenidate, Methylphenidate, Dextroamphetamine, Theophylline Oral and Morphine Sulfate in the US.